BR112018070357A2 - anticorpos anticomplemento contra o fator bb e seus usos - Google Patents

anticorpos anticomplemento contra o fator bb e seus usos

Info

Publication number
BR112018070357A2
BR112018070357A2 BR112018070357A BR112018070357A BR112018070357A2 BR 112018070357 A2 BR112018070357 A2 BR 112018070357A2 BR 112018070357 A BR112018070357 A BR 112018070357A BR 112018070357 A BR112018070357 A BR 112018070357A BR 112018070357 A2 BR112018070357 A2 BR 112018070357A2
Authority
BR
Brazil
Prior art keywords
antibodies against
complement
against factor
complement antibodies
antibodies
Prior art date
Application number
BR112018070357A
Other languages
English (en)
Inventor
Parry Graham
Sue Christopherson Karen
Panicker Sandip
Sangyoung Byun Tony
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of BR112018070357A2 publication Critical patent/BR112018070357A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente descrição refere-se a anticorpos anticomplemento contra o fator bb e composições compreendendo os anticorpos. os anticorpos anti-bb são úteis para o tratamento de distúrbios mediados pelo complemento. a presente descrição refere-se a métodos de tratamento de distúrbios mediados por complemento.
BR112018070357A 2016-04-04 2017-04-03 anticorpos anticomplemento contra o fator bb e seus usos BR112018070357A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112018070357A2 true BR112018070357A2 (pt) 2019-01-29

Family

ID=60000646

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070357A BR112018070357A2 (pt) 2016-04-04 2017-04-03 anticorpos anticomplemento contra o fator bb e seus usos

Country Status (23)

Country Link
US (2) US10934347B2 (pt)
EP (1) EP3452510A4 (pt)
JP (3) JP6967528B2 (pt)
KR (1) KR102673420B1 (pt)
CN (2) CN109563158B (pt)
AU (1) AU2017246794A1 (pt)
BR (1) BR112018070357A2 (pt)
CA (1) CA3019332A1 (pt)
CL (1) CL2018002810A1 (pt)
CO (1) CO2018010827A2 (pt)
CR (1) CR20180529A (pt)
DO (1) DOP2018000219A (pt)
EA (1) EA201892225A1 (pt)
EC (1) ECSP18082302A (pt)
IL (3) IL311675A (pt)
MA (1) MA44878A (pt)
MX (2) MX2018012176A (pt)
MY (1) MY194603A (pt)
PE (1) PE20190209A1 (pt)
PH (1) PH12018502137A1 (pt)
SG (1) SG11201808525UA (pt)
TN (1) TN2018000341A1 (pt)
WO (1) WO2017176651A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018070357A2 (pt) 2016-04-04 2019-01-29 Bioverativ Usa Inc anticorpos anticomplemento contra o fator bb e seus usos
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
CN111527105A (zh) * 2017-10-11 2020-08-11 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
JP7403165B2 (ja) * 2017-12-19 2023-12-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血液脳関門を通過してウイルスベクターを送達するための方法および組成物
EP3990015A4 (en) * 2019-06-27 2023-04-26 Verseau Therapeutics, Inc. ANTI-CD53 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY PHENOTYPES OF MYELOID CELLS AND THEIR USES
KR20220057530A (ko) * 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
US20230050339A1 (en) * 2020-02-18 2023-02-16 Children's Hospital Medical Center Compositions and methods for treating liver disease
US11242382B2 (en) 2020-04-20 2022-02-08 Genzyme Corporation Humanized anti-complement factor Bb antibodies

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
EP1285960A3 (en) 1994-12-09 2003-05-07 Imperial College Innovations Limited Virulence genes from Salmonella typhimurium
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DE69708318T3 (de) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AR014621A1 (es) 1997-12-12 2001-03-28 Macromed Inc Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1713503B1 (en) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
KR20150055628A (ko) 2005-11-04 2015-05-21 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
SG10201602095PA (en) * 2005-12-20 2016-05-30 Sbi Biotech Co Ltd Anti-Ilt7 Antibody
WO2009029669A1 (en) * 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
MX2010005115A (es) * 2007-11-08 2010-05-27 Genentech Inc Anticuerpos anti-factor b y sus usos.
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
RU2014120694A (ru) 2011-10-27 2015-12-10 Нкт Терапьютикс Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К iNKT
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
CN104220454B (zh) * 2012-04-03 2018-09-07 诺沃姆德治疗公司 人源化的嵌合抗因子Bb抗体及其用途
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
JP6462591B2 (ja) 2013-02-22 2019-01-30 アッヴィ・ステムセントルクス・エル・エル・シー 新規抗体コンジュゲートおよびその使用
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
BR112016019825A2 (pt) * 2014-02-27 2017-10-17 Allergan Inc anticorpos do fator bb do complemento
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
BR112018070357A2 (pt) 2016-04-04 2019-01-29 Bioverativ Usa Inc anticorpos anticomplemento contra o fator bb e seus usos
CN111527105A (zh) 2017-10-11 2020-08-11 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
US11242382B2 (en) 2020-04-20 2022-02-08 Genzyme Corporation Humanized anti-complement factor Bb antibodies

Also Published As

Publication number Publication date
JP6967528B2 (ja) 2021-11-17
DOP2018000219A (es) 2019-03-31
CL2018002810A1 (es) 2019-03-15
SG11201808525UA (en) 2018-10-30
CN116790614A (zh) 2023-09-22
MY194603A (en) 2022-12-06
EP3452510A4 (en) 2020-01-15
PH12018502137A1 (en) 2019-09-23
IL311675A (en) 2024-05-01
US11851482B2 (en) 2023-12-26
MX2018012176A (es) 2019-02-07
IL262010A (en) 2018-10-31
JP2023139289A (ja) 2023-10-03
US10934347B2 (en) 2021-03-02
US20190153079A1 (en) 2019-05-23
IL295288B1 (en) 2024-04-01
JP2019513726A (ja) 2019-05-30
CN109563158B (zh) 2022-08-09
MX2023007149A (es) 2023-06-28
IL262010B (en) 2022-09-01
CN109563158A (zh) 2019-04-02
KR102673420B1 (ko) 2024-06-07
EA201892225A1 (ru) 2019-09-30
US20210221877A1 (en) 2021-07-22
JP2021191789A (ja) 2021-12-16
KR20190003951A (ko) 2019-01-10
EP3452510A1 (en) 2019-03-13
TN2018000341A1 (en) 2020-06-15
IL295288A (en) 2022-10-01
MA44878A (fr) 2019-03-13
JP7326393B2 (ja) 2023-08-15
PE20190209A1 (es) 2019-02-07
AU2017246794A1 (en) 2018-10-25
WO2017176651A1 (en) 2017-10-12
CR20180529A (es) 2019-03-21
ECSP18082302A (es) 2019-01-31
CA3019332A1 (en) 2017-10-12
CO2018010827A2 (es) 2018-11-22

Similar Documents

Publication Publication Date Title
BR112018070357A2 (pt) anticorpos anticomplemento contra o fator bb e seus usos
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
EA201990043A1 (ru) Антибактериальные соединения
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
EA201890204A1 (ru) Антибактериальные соединения
BR112018069533A2 (pt) tratamento de condições alérgicas oculares com ciclodextrinas
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
NI201500117A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
EA201691582A1 (ru) Новые фармацевтические препараты
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112016028255A2 (pt) agentes imunorreguladores
GT201700188A (es) Anticuerpos contra tau y sus usos
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
PH12020550023A1 (en) Compositions for treating stress-related disorders
EA201990400A1 (ru) Соединения и композиции и их применение
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
MX2022015456A (es) Composiciones de maca y metodos de uso.
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]